The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Hagenbuch, B., & Meier, P. J. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1168-y · Cited by 1,019
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Self-citationThe role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
The superfamily of organic anion transporting polypeptides
Hagenbuch, B., & Meier, P. J. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00633-8 · Cited by 861
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Self-citationXenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Self-citationKullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 723
Tamai, I., Nezu, J.-I., Uchino, H., Sai, Y., Oku, A., Shimane, M., & Tsuji, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2922 · Cited by 642
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 611
Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1
Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17159 · Cited by 543
Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001448200 · Cited by 522
Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin
Fischer, W. J., Altheimer, S., Cattori, V., Meier, P. J., Dietrich, D. R., & Hagenbuch, B. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.08.012 · Cited by 520
Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6
Cui, Y., König, J., Leier, I., Buchholz, U., & Keppler, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004968200 · Cited by 515
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.053 · Cited by 502
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Self-citationContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
Self-citationKullak-Ublick, G. A., Hagenbuch, B., Stieger, B., Schteingart, C. D., Hofmann, A. F., Wolkoff, A. W., & Meier, P. J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90588-x · Cited by 428
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Self-citationKobayashi, D., Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051300 · Cited by 416
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 416
Self-citationSLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationShitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans
Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S., Jolicoeur, E., Lee, W., Leake, B. F., Tirona, R. G., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100056 · Cited by 407
Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M., & Chiba, K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000170913.73780.5f · Cited by 379
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
Vavricka, S. R., Van Montfoort, J., Ha, H. R., Meier, P. J., & Fattinger, K. (2002) · Hepatology · doi:10.1053/jhep.2002.34133 · Cited by 373
Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin
Kitamura, S., Maeda, K., Wang, Y., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021410 · Cited by 361
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Self-citationWatanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., & Sugiyama, Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146647 · Cited by 351
Treviño, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., Chan, D., Sparreboom, A., Giacomini, K. M., Pui, C.-H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4156 · Cited by 349
Abe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.24804 · Cited by 345
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Transporter Pharmacogenetics and Statin Toxicity
Niemi, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.197 · Cited by 330
Self-citationOgilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 330
Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Tirona, R. G., Leake, B. F., Wolkoff, A. W., & Kim, R. B. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043026 · Cited by 324
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J.-I., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 318
Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., & Tamai, I. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001909 · Cited by 316
Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y., & Fardel, O. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010033 · Cited by 315
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
Treiber, A., Schneiter, R., Häusler, S., & Stieger, B. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013615 · Cited by 299
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Schneck, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292
Noé, J., Portmann, R., Brun, M.-E., & Funk, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012930 · Cited by 291
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 286
Self-citationNiemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
Self-citationThe Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
Fenner, K., Troutman, M., Kempshall, S., Cook, J., Ware, J., Smith, D., & Lee, C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.195 · Cited by 272
Role of OATP Transporters in the Disposition of Drugs
Niemi, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.787 · Cited by 266
Self-citationPlasma concentrations of active simvastatin acid are increased by gemfibrozil
Backman, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108507 · Cited by 264
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
NIEMI, M., PASANEN, M., & NEUVONEN, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.010 · Cited by 250
Self-citationJacobson, T. A. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.07.080 · Cited by 243
Leonhardt, M., Keiser, M., Oswald, S., Kühn, J., Jia, J., Grube, M., Kroemer, H. K., Siegmund, W., & Weitschies, W. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032862 · Cited by 240
Genome-wide association meta-analysis for total serum bilirubin levels
Johnson, A. D., Kavousi, M., Smith, A. V., Chen, M.-H., Dehghan, A., Aspelund, T., Lin, J.-P., van Duijn, C. M., Harris, T. B., Cupples, L. A., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp202 · Cited by 238
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel
Smith, N. F., Acharya, M. R., Desai, N., Figg, II, & Sparreboom, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.8.1867 · Cited by 234
Sasaki, M., Suzuki, H., Ito, K., Abe, T., & Sugiyama, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109081200 · Cited by 228
van de Steeg, E., Wagenaar, E., van der Kruijssen, C. M. M., Burggraaff, J. E. C., de Waart, D. R., Elferink, R. P. J. O., Kenworthy, K. E., & Schinkel, A. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42168 · Cited by 226
Nakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T., & Nishimura, K. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29609-9 · Cited by 217
Man, M., Farmen, M., Dumaual, C., Teng, C. H., Moser, B., Irie, S., Noh, G. J., Njau, R., Close, S., Wise, S., et al. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009355161 · Cited by 216
GRUBE, M., KOCK, K., OSWALD, S., DRABER, K., MEISSNER, K., ECKEL, L., BOHM, M., FELIX, S., VOGELGESANG, S., & JEDLITSCHKY, G. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.010 · Cited by 215
An association study of 43 SNPs in 16 candidate genes with atorvastatin response
Thompson, J. F., Man, M., Johnson, K. J., Wood, L. S., Lira, M. E., Lloyd, D. B., Banerjee, P., Milos, P. M., Myrand, S. P., Paulauskis, J., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500328 · Cited by 214
Tamai, I., Nozawa, T., Koshida, M., Nezu, J.-I., Sai, Y., & Tsuji, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1013077609227 · Cited by 211
Chen, C., Mireles, R. J., Campbell, S. D., Lin, J., Mills, J. B., Xu, J. J., & Smolarek, T. A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002477 · Cited by 209
Seithel, A., Eberl, S., Singer, K., Auge, D., Heinkele, G., Wolf, N. B., Dörje, F., Fromm, M. F., & König, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014407 · Cited by 207
Cyclosporine markedly raises the plasma concentrations of repaglinide
KAJOSAARI, L., NIEMI, M., NEUVONEN, M., LAITILA, J., NEUVONEN, P., & BACKMAN, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.005 · Cited by 207
Self-citationYamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008938 · Cited by 202
MAEDA, K., IEIRI, I., YASUDA, K., FUJINO, A., FUJIWARA, H., OTSUBO, K., HIRANO, M., WATANABE, T., KITAMURA, Y., & KUSUHARA, H. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.011 · Cited by 200
Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirona, R. G., Bailey, D. G., Michael Stein, C., & Kim, R. B. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3280ef698f · Cited by 199
Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells
Kopplow, K., Letschert, K., König, J., Walter, B., & Keppler, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014605 · Cited by 197
Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191
Self-citationMatsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., & Sugiyama, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085589 · Cited by 190
Keskitalo, J. E., Pasanen, M. K., Neuvonen, P. J., & Niemi, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.85 · Cited by 189
Self-citationGemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1181-x · Cited by 186
Self-citationGlobal Analysis of Genetic Variation in SLCO1B1
Pasanen, M. K., Neuvonen, P. J., & Niemi, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.19 · Cited by 183
Self-citationChen, Z.-S., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M., & Akiyama, S.-I. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1219 · Cited by 178
Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009175 · Cited by 178
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., Sora, E. S., James, C. E., Gibbons, S., Bray, P. G., et al. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328335b02d · Cited by 176
BRIZ, O., SERRANO, M. A., MACIAS, R. I. R., GONZALEZ-GALLEGO, J., & MARIN, J. J. G. (2003) · Biochemical Journal · doi:10.1042/bj20030034 · Cited by 175
Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3
Gui, C., Miao, Y., Thompson, L., Wahlgren, B., Mock, M., Stieger, B., & Hagenbuch, B. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.042 · Cited by 174
Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin
Kajosaari, L. I., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_157.x · Cited by 172
Self-citationJung, D., Hagenbuch, B., Gresh, L., Pontoglio, M., Meier, P. J., & Kullak-Ublick, G. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103988200 · Cited by 170
Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
CHUNG, J., CHO, J., YU, K., KIM, J., OH, D., JUNG, H., LIM, K., MOON, K., SHIN, S., & JANG, I. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.003 · Cited by 170
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1
Annaert, P., Ye, Z., Stieger, B., & Augustijns, P. (2010) · Xenobiotica · doi:10.3109/00498250903509375 · Cited by 169
Meier‐Abt, F., Mokrab, Y., & Mizuguchi, K. (2006) · The Journal of Membrane Biology · doi:10.1007/s00232-005-7004-x · Cited by 168
Picard, N., Yee, S. W., Woillard, J.-B., Lebranchu, Y., Le Meur, Y., Giacomini, K. M., & Marquet, P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.205 · Cited by 165
Olbricht, C., Wanner, C., Eisenhauer, T., Kliem, V., Doll, R., Boddaert, M., O'Grady, P., Krekler, M., Mangold, B., & Christians, U. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90034-5 · Cited by 165
Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100190 · Cited by 164
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
Kyrklund, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111414 · Cited by 163
Lu, H., Choudhuri, S., Ogura, K., Csanaky, I. L., Lei, X., Cheng, X., Song, P.-Z., & Klaassen, C. D. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn038 · Cited by 163
Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers
Kiser, J. J., Gerber, J. G., Predhomme, J. A., Wolfe, P., Flynn, D. M., & Hoody, D. W. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318160a542 · Cited by 160
MUCK, W., MAI, I., FRITSCHE, L., OCHMANN, K., ROHDE, G., UNGER, S., JOHNE, A., BAUER, S., BUDDE, K., & ROOTS, I. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70104-9 · Cited by 158
Backman, J. T., Luurila, H., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.007 · Cited by 156
Self-citationMiura, M., Satoh, S., Inoue, K., Kagaya, H., Saito, M., Inoue, T., Suzuki, T., & Habuchi, T. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0380-7 · Cited by 150
Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus
Lemahieu, W. P. D., Hermann, M., Åsberg, A., Verbeke, K., Holdaas, H., Vanrenterghem, Y. F. C., & Maes, B. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01005.x · Cited by 149
Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K., & Sugiyama, Y. (2004) · Pharmacogenetics · doi:10.1097/00008571-200411000-00006 · Cited by 147
Campbell, S. D., de Morais, S. M., & Xu, J. J. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.08.008 · Cited by 144
Yamada, A., Maeda, K., Kamiyama, E., Sugiyama, D., Kondo, T., Shiroyanagi, Y., Nakazawa, H., Okano, T., Adachi, M., Schuetz, J. D., et al. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017459 · Cited by 143
Michalski, C. W., Cui, Y., Nies, A. T., Nussler, A. K., Neuhaus, P., Zanger, U. M., Klein, K., Eichelbaum, M. F., KEPPLER, D. O. R., & König, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207735200 · Cited by 140
Árnadóttir, M., Eriksson, L.-O., Thysell, H., & Karkas, J. D. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000187521 · Cited by 137
Niemi, M., Kivistö, K. T., Hofmann, U., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02354.x · Cited by 135
Self-citationAmundsen, R., Christensen, H., Zabihyan, B., & Åsberg, A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032268 · Cited by 135
Neuvonen, P. J. (2010) · PubMed · Cited by 133
Self-citationInfluence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans
Choi, J., Lee, M., Cho, J.-Y., Lee, J.-E., Kim, K. H., & Park, K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100267 · Cited by 131
Ichimaru, N., Takahara, S., Kokado, Y., Wang, J. D., Hatori, M., Kameoka, H., Inoue, T., & Okuyama, A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00438-5 · Cited by 130
Sanna, S., Busonero, F., Maschio, A., McArdle, P. F., Usala, G., Dei, M., Lai, S., Mulas, A., Piras, M. G., Perseu, L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp203 · Cited by 128
Åsberg, A., Hartmann, A., Fjeldså, E., Bergan, S., & Holdaas, H. (2001) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2001.10415.x · Cited by 127
Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M. G., Lütjohann, D., von Bergmann, K., Eichelbaum, M. F., & Kivistö, K. T. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00005 · Cited by 125
Self-citationDeng, J. W., Song, I., Shin, H. J., Yeo, C., Cho, D., Shon, J., & Shin, J. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282fb02a3 · Cited by 125
van de Steeg, E., van der Kruijssen, C. M. M., Wagenaar, E., Burggraaff, J. E. C., Mesman, E. M., Kenworthy, K. E., & Schinkel, A. H. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024315 · Cited by 125
Zheng, H., Huang, Y. L., Frassetto, L. A., & Benet, L. Z. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.186 · Cited by 125
Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters
Bachmakov, I., Glaeser, H., Fromm, M. F., & König, J. (2008) · Diabetes · doi:10.2337/db07-1515 · Cited by 125
Briz, Ó., Serrano, M. A., Rebollo, N., Hagenbuch, B., Meier, P. J., Koepsell, H., & Marı́n, J. J. G. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.4.853 · Cited by 124
Nozawa, T., Sugiura, S., Nakajima, M., Goto, A., Yokoi, T., Nezu, J., Tsuji, A., & Tamai, I. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.291 · Cited by 121
The genetics of statin-induced myopathy
Ghatak, A., Faheem, O., & Thompson, P. D. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.033 · Cited by 120
Pasanen, M. K., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0123-1 · Cited by 119
Self-citationEffects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.266 · Cited by 119
Self-citationZaher, H., zu Schwabedissen, H. E. M., Tirona, R. G., Cox, M. L., Obert, L., Agrawal, N., Palandra, J., Stock, J. L., Kim, R. B., & Ware, J. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046458 · Cited by 117
Lubomirov, R., di Iulio, J., Fayet, A., Colombo, S. F., Martínez, R., Marzolini, C., Furrer, H., Vernazza, P., Calmy, A., Cavassini, M. L., et al. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328336eee4 · Cited by 116
Regazzi, M. B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A., & Viganò, M. (1993) · PubMed · Cited by 114
Buch, S., Schafmayer, C., Völzke, H., Seeger, M., Miquel, J. F., Sookoian, S. C., Egberts, J. H., Arlt, A., Pirola, C. J., Lerch, M. M., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.003 · Cited by 113
Watanabe, T., Kusuhara, H., & Sugiyama, Y. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9176-y · Cited by 111
HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN
Sandhu, P., Lee, W., Xu, X., Leake, B. F., Yamazaki, M., Stone, J. A., Lin, J. H., Pearson, P. G., & Kim, R. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003244 · Cited by 109
Igel, M., ARNOLD, K., Niemi, M., Hofmann, U., Schwab, M. G., Lütjohann, D., VONBERGMANN, K., Eichelbaum, M. F., & Kivistö, K. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.010 · Cited by 108
Self-citationFahrmayr, C., Fromm, M. F., & König, J. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491683 · Cited by 108
Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin
Busti, A. J., Bain, A. M., Hall, R. G., Bedimo, R. G., Leff, R. D., Meek, C. C., & Mehvar, R. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31817b5b5a · Cited by 107
Gui, C., Obaidat, A., Chaguturu, R., & Hagenbuch, B. (2010) · Current Chemical Genomics · doi:10.2174/1875397301004010001 · Cited by 107
Han, J., Lim, H., Park, Y. H., Lee, S., & Lee, J. S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.003 · Cited by 107
Fehrenbach, T., Cui, Y., Faulstich, H., & KEPPLER, D. O. R. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0814-4 · Cited by 106
Fujino, H., Saito, T., Ogawa, S.-I., & Kojima, J. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.10.0009 · Cited by 104
Liu, L., Cui, Y., Chung, A. Y., Shitara, Y., Sugiyama, Y., KEPPLER, D. O. R., & Pang, K. S. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103390 · Cited by 103
Pharmacokinetics of the combination of fluvastatin and gemfibrozil
Spence, J. D., Muñoz, C. E., Hendricks, L., Latchinian, L., & Khouri, H. E. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80024-4 · Cited by 102
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide
Zhang, W., He, Y., Han, C., Liu, Z., Li, Q., Fan, L., Tan, Z., Zhang, W., Yu, B., Wang, D., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02686.x · Cited by 101
Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1
Oswald, S., König, J., Lütjohann, D., Gießmann, T., Kroemer, H. K., Rimmbach, C., Rosskopf, D., Fromm, M. F., & Siegmund, W. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282fe9a2c · Cited by 101
Nakagomi, R., Nakai, D., Kawai, K., Yoshigae, Y., Tokui, T., Abe, T., & Ikeda, T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008888 · Cited by 100
Katz, D. A., Carr, R. A., GRIMM, D., Xiong, H., Holley-Shanks, R. R., MUELLER, T., Leake, B. F., WANG, Q., Han, L., & WANG, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.003 · Cited by 99
Kalliokoski, A., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007311569 · Cited by 99
Self-citationRenal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A
Binet, I., Wallnöfer, A., Weber, C., Jones, R. D., & Thiel, G. T. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00838.x · Cited by 97
Morimoto, K., Oishi, T., Ueda, S., Ueda, M., Hosokawa, M., & Chiba, K. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.453 · Cited by 96
Xiang, X., Jada, S. R., Li, H. H., Fan, L., Tham, L. S., Wong, C. I., Lee, S. C., Lim, R. S. C., Zhou, Q. Y., Goh, B. C., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230420.05221.71 · Cited by 93
Hedman, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.011 · Cited by 93
Han, J., Lim, H., Shin, E., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Kim, H. T., & Lee, J. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.019 · Cited by 92
Hepatic Transport Mechanisms of Cholyl-l-Lysyl-Fluorescein
de Waart, D. R., Häusler, S., Vlaming, M. L. H., Kunne, C., Hänggi, E., Gruss, H.-J., Elferink, R. P. J. O., & Stieger, B. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166991 · Cited by 92
Couvert, P., Giral, P., Dejager, S., Gu, J. Z., Huby, T., Chapman, M. J., Bruckert, É., & Carrié, A. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1217 · Cited by 90
Chang, C. K., Pang, K. S., Swaan, P. W., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082370 · Cited by 88
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism
He, Y., Zhang, W., Chen, Y., Guo, D., Tu, J., Xu, L., Tan, Z., Chen, B., Li, Z., Zhou, G., et al. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.04.003 · Cited by 88
Matsushima, S., Maeda, K., Ishiguro, N., Igarashi, T., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017814 · Cited by 88
The effect of erythromycin on the pharmacokinetics of rosuvastatin
Cooper, K. J., Martin, P. D., Dane, A. L., Warwick, M. J., Raza, A., & Schneck, D. W. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0573-7 · Cited by 87
Iida, A., Saito, S., Sekine, A., Mishima, C., Kondo, K., Kitamura, Y., Harigae, S., Osawa, S., & Nakamura, Y. (2001) · Journal of Human Genetics · doi:10.1007/s100380170019 · Cited by 87
Miura, M., Kagaya, H., Satoh, S., et al. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181838063 · Cited by 85
Liver X Receptor α and Farnesoid X Receptor Are Major Transcriptional Regulators of OATP1B1
zu Schwabedissen, H. E. M., Böttcher, K., Chaudhry, A. S., Kroemer, H. K., Schuetz, E. G., & Kim, R. B. (2010) · Hepatology · doi:10.1002/hep.23876 · Cited by 84
Kalliokoski, A., Backman, J. T., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.74 · Cited by 84
Self-citationPrediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
Poirier, A., Cascais, A., Funk, C., & Lavé, T. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9139-3 · Cited by 83
Maeda, K., Kambara, M., Tian, Y., Hofmann, A. F., & Sugiyama, Y. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050063u · Cited by 79
Park, J., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaroß, W. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600404 · Cited by 78
Rao, U. S. M., & Scarborough, G. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10165-x · Cited by 78
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects
Kyrklund, C., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01972.x · Cited by 77
Self-citationGenome-wide association of serum bilirubin levels in Korean population
Kang, T.-W., Kim, H., Ju, H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq281 · Cited by 77
Kohlrausch, F. B., Estrela, R. D. C. E., Barroso, P. F., & Suarez‐Kurtz, G. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03551.x · Cited by 76
Interactions of Cyclosporin A with Breast Cancer Resistance Protein
Xia, C. Q., Liu, N., Miwa, G. T., et al. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011866 · Cited by 76
Yamaguchi, H., Kobayashi, M., Okada, M., Takeuchi, T., Unno, M., Abe, T., Goto, J., Hishinuma, T., & Mano, N. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.10.040 · Cited by 76
Marzolini, C., Tirona, R. G., Gervasini, G., Balasubramanian, P., Assem, M., Lee, W., Leake, B. F., Schuetz, J. D., Schuetz, E. G., & Kim, R. B. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0025 · Cited by 73
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
Kalliokoski, A., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03287.x · Cited by 70
Self-citationHermann, M., Åsberg, A., Christensen, H., Holdaas, H., Hartmann, A., & Reubsaet, L. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.008 · Cited by 69
Kalliokoski, A., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830d733e · Cited by 68
Self-citationNakakariya, M., Shimada, T., Irokawa, M., Maeda, T., & Tamai, I. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.347 · Cited by 67
Gender Is an Important Determinant of the Disposition of the Loop Diuretic Torasemide
Werner, U., Werner, D., Heinbüchner, S., Graf, B., İnce, H., Kische, S., Thürmann, P., König, J., Fromm, M. F., & Zolk, O. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337514 · Cited by 66
Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells
Fardel, O., Lecureur, V., Loyer, P., & Guillouzo, A. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00045-2 · Cited by 65
Bednarczyk, D. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.06.012 · Cited by 64
Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics
Becquemont, L., Neuvonen, M., Verstuyft, C., Jaillon, P., Letierce, A., Neuvonen, P. J., & Funck‐Brentano, C. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100098 · Cited by 64
Self-citationvan der Deure, W. M., Friesema, E. C. H., de Jong, F. J., de Rijke, Y. B., de Jong, F. H., Uitterlinden, A. G., Breteler, M. M. B., Peeters, R. P., & Visser, T. J. (2008) · Endocrinology · doi:10.1210/en.2008-0169 · Cited by 64
Xiang, X., Han, Y., Neuvonen, M., Pasanen, M. K., Kalliokoski, A., Backman, J. T., Laitila, J., Neuvonen, P. J., & Niemi, M. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832bcf7b · Cited by 61
Self-citationKalliokoski, A., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02986.x · Cited by 61
Self-citationRosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C
Brown, C., Windass, A. S., Bleasby, K., & Lauffart, B. (2001) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(01)80225-7 · Cited by 60
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
INNOCENTI, F., UNDEVIA, S., RAMIREZ, J., MANI, S., SCHILSKY, R., VOGELZANG, N., PRADO, M., & RATAIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.016 · Cited by 57
Ni, W., Ji, J., Dai, Z., Papp, A. C., Johnson, A. J., Ahn, S., Farley, K. L., Lin, T. S., Dalton, J. T., Li, X., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013792 · Cited by 57
Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations
Mwinyi, J., Köpke, K., Schaefer, M., Roots, I., & Gerloff, T. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0409-y · Cited by 54
Weaver, Y. M., & Hagenbuch, B. (2010) · The Journal of Membrane Biology · doi:10.1007/s00232-010-9300-3 · Cited by 53
Aquilante, C. L., Bushman, L. R., Knutsen, S. D., Burt, L. E., Rome, L. C., & Kosmiski, L. A. (2008) · Human Genomics · doi:10.1186/1479-7364-3-1-7 · Cited by 53
Fox, R. I., Morgan, S., Smith, H. T., Robbins, B. A., Choc, M. G., & Baggott, J. E. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg277 · Cited by 52
Oostendorp, R. L., van de Steeg, E., van der Kruijssen, C. M. M., Beijnen, J. H., Kenworthy, K. E., Schinkel, A. H., & Schellens, J. H. M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024901 · Cited by 49
SLCO1B1Polymorphism and Oral Antidiabetic Drugs
Kalliokoski, A., Neuvonen, P. J., & Niemi, M. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00581.x · Cited by 42
Self-citationWerner, D., Werner, U., Meybaum, A., Schmidt, B., Umbreen, S., Grosch, A., Lestin, H., Graf, B., Zolk, O., & Fromm, M. F. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00003 · Cited by 41
Vormfelde, S. V., Toliat, M., Schirmer, M., Meineke, I., Nürnberg, P., & Brockmöller, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100404 · Cited by 41
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Marty, F. M., Ljungman, P., Chemaly, R. F., Maertens, J., Dadwal, S. S., Duarte, R. F., Haider, S., Ullmann, A. J., Katayama, Y., Brown, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706640 · Cited by 1,238
The Blood-Testis Barrier and Its Implications for Male Contraception
Cheng, C. Y., & Mruk, D. D. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.002790 · Cited by 927
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Metadata
- Authors
- Niemi, M., Pasanen, M. K., & Neuvonen, P. J.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 63
- Issue
- 1
- Pages
- 157-181
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2113719939
- Cited by
- 633
- References
- 218
- FWCI
- 29.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.